Skip to content

MDMA in two dose strengths shows effectiveness in reducing PTSD symptoms

The Brown University Psychopharmacology Update September 1, 2018 DOI: 10.1002/pu.30352 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Population Military veterans and public safety officers with chronic post-traumatic stress disorder
Interventions MDMA Psychotherapy
Dose 75 mg, 125 mg, and 30 mg control
Duration Two experimental sessions spaced 3 to 5 weeks apart
Topics MDMA PTSD
Key findings Doses of 75 mg and 125 mg of MDMA given with psychotherapy were more effective than a 30 mg control dose in reducing PTSD symptoms.

Abstract

Military veterans and public safety officers with chronic post‐traumatic stress disorder (PTSD) experienced a reduction in symptoms when the psychedelic drug 3,4‐methylenedioxymethamphetamine (MDMA) was given in conjunction with psychotherapy, a randomized trial has found. Doses of 75 mg and 125 mg, each given in two experimental sessions spaced 3 to 5 weeks apart, were more effective than a control dose of 30 mg, researchers reported.

Related reading